Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Material Agreement (Apr 6, 2026)

Reports
Material Agreements·Exhibits & Filings
Filing Date
Filed April 6, 2026
Period End
April 5, 2026
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · Apr ’21Apr ’21
  3. Leadership change8-K · May ’25May ’25

Summary

Summary of the 8-K filed April 6, 2026. Cited figures are marked; the original filing is the authoritative source.

On April 5, 2026, Neurocrine Biosciences, Inc. entered into an Agreement and Plan of Merger with Soleno Therapeutics, Inc. under which Neurocrine, through a wholly owned subsidiary, will commence a cash tender offer for all outstanding Soleno shares at $53.00a per share.

The press release attached as Exhibit 99.1 describes a total transaction equity value of $2.9 billionb, to be funded with cash on hand and a modest amount of pre-payable debt, with no financing condition. The transaction is expected to close within 90 days of the April 6, 2026 announcement, subject to customary conditions including the expiration or termination of the HSR Act waiting period. The offer price represents a premium of approximately 34% to Soleno's April 2, 2026 closing share price and 51% to its 30-day VWAP, according to the press release.

The deal centers on VYKAT XR (diazoxide choline), which the filing describes as the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome. The press release states VYKAT XR generated $190 millionc in 2025 revenue, including $92 million in the fourth quarter. Neurocrine expects the acquisition to add a product to its existing commercial portfolio alongside INGREZZA ($2.51 billion in 2025 revenue) and CRENESSITY ($301 million in 2025 revenue), and to support revenue growth and diversification.

The merger agreement includes a $95,250,000d termination fee payable by Soleno in specified circumstances, including to accept a superior proposal, and a $141,500,000 reverse termination fee payable by Neurocrine if the HSR or antitrust-related conditions are not satisfied at termination. Soleno's CEO and Chairman Anish Bhatnagar and former CFO James Mackaness signed Tender and Support Agreements covering approximately 1.01% of outstanding Shares as of April 5, 2026. Soleno's board recommends that stockholders tender their shares.

Key Highlights

  1. Neurocrine will acquire Soleno for $53.00 per share in cash via a tender offer followed by a second-step merger under DGCL Section 251(h), with a total equity value of $2.9 billion per the press release.
  2. The offer is not subject to a financing condition; Neurocrine plans to fund the deal with cash on hand and a modest amount of pre-payable debt.
  3. Offer premium is stated as approximately 34% to Soleno's April 2, 2026 closing price and 51% to its 30-day VWAP.
  4. VYKAT XR generated $190 million in 2025 revenue, including $92 million in Q4 2025, per the press release; the company describes it as the first and only FDA-approved therapy for hyperphagia in Prader-Willi syndrome.
  5. Termination fee of $95,250,000 payable by Soleno in specified circumstances, and a reverse termination fee of $141,500,000 payable by Neurocrine if antitrust-related conditions are not satisfied.
  6. Closing conditions include a minimum tender of more than 50% of outstanding Shares, expiration of the HSR waiting period, absence of a material adverse effect on Soleno, and other customary conditions; the transaction is expected to close within 90 days of announcement.
  7. Soleno's CEO and Chairman and a former CFO entered Tender and Support Agreements covering approximately 1.01% of outstanding Shares.

Frequently Asked Questions

  1. What is the price and total value of the proposed acquisition?

    Neurocrine will pay $53.00 per Soleno share in cash, representing a total transaction equity value of $2.9 billion according to the joint press release attached as Exhibit 99.1.

  2. How will the deal be financed and is there a financing condition?

    The transaction will be funded with cash on hand, and Neurocrine plans to optimize its capital structure by taking on a modest amount of pre-payable debt. The offer is not subject to any financing condition.

  3. What conditions must be met for the tender offer and merger to close?

    Key conditions include more than 50% of outstanding Shares being validly tendered and not withdrawn, the accuracy of Soleno's representations subject to materiality exceptions, performance of Soleno's covenants, no material adverse effect on Soleno, expiration or termination of the HSR Act waiting period, and no governmental order prohibiting the deal. The press release says closing is expected within 90 days of announcement.

  4. What termination fees apply if the deal fails?

    Soleno would pay Neurocrine a termination fee of $95,250,000 in specified circumstances, such as terminating to accept a superior proposal. Neurocrine would pay Soleno a reverse termination fee of $141,500,000 if the HSR Act waiting period or certain antitrust-related governmental restraints have not been satisfied at termination.

  5. What does Neurocrine gain from the acquisition?

    Neurocrine states the acquisition adds VYKAT XR, which generated $190 million in 2025 revenue for Soleno, to a portfolio that will include INGREZZA and CRENESSITY, and is expected to diversify its revenue base and support growth. The company says VYKAT XR's intellectual property is expected to extend into the mid-2040s.